STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

How 1 sources are covering this

• STATCenter·1h ago

  STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

  Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

  Read at STAT →